Dr. Nevala-Plagemann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2000 Circle of Hope
Salt Lake City, UT 84112Phone+1 801-646-4207Fax+1 801-581-7532
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2019 - 2022- University of Utah HealthResidency, Internal Medicine, 2015 - 2019
University of Minnesota Medical SchoolClass of 2015
Certifications & Licensure
UT State Medical License 2017 - 2026
CO State Medical License 2022 - 2025
ID State Medical License 2022 - 2025
NV State Medical License 2022 - 2025
WY State Medical License 2022 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma.Carter Norton, Matthew Steven Shaw, Zachary Rubnitz, Jarrod Smith, Heloisa P Soares
JAMA Network Open. 2025-01-02 - Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3'.Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna
Nature Reviews. Clinical Oncology. 2024-12-01 - 3 citationsNALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?Christopher Nevala-Plagemann, Ignacio Garrido-Laguna
Nature Reviews. Clinical Oncology. 2024-08-01
Press Mentions
Real-World Data Show Regorafenib on Par with TAS-102 in Metastatic CRCMarch 3rd, 2023- Liposomal Irinotecan for Pancreatic Cancer: Is It Worth It?May 25th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
